Community-level factors influencing the duration of buprenorphine treatment in individuals with opioid use disorder: a cohort study using US longitudinal claims data

Paula A Jaimes-Buitron, Kehe Zhang, Yanmin Gong, Yuanxiong Guo, Cici Bauer, Carolina Vivas-ValenciaBMJ 2025 · DOI

Abstract: Social vulnerability, provider availability and mental health service access are significantly associated with buprenorphine treatment duration. Addressing these access inequities could improve retention for individuals with OUD.

Introduction

Opioid Use Disorder (OUD) remains a catastrophic public health emergency in the United States. While buprenorphine is an evidence-based, gold-standard treatment that significantly reduces overdose risk, keeping patients on the medication—known as treatment retention—is a major hurdle. Many patients discontinue therapy within the first 90 days, a period of extreme vulnerability for relapse and death.

Traditionally, research has focused on individual-level predictors of retention, such as age, sex, or co-occurring psychiatric conditions. However, this "individualistic" view often ignores the structural environment. A study published in BMJ Public Health investigates how the "where" of a patient’s life—their community context—influences their ability to stay on buprenorphine. By linking longitudinal insurance claims with geographic data on social vulnerability and healthcare access, the researchers demonstrate that community-level factors are primary drivers of long-term treatment retention.

Methods

The researchers conducted a retrospective cohort study tracking 131,169 individuals (representing over 303,000 treatment episodes) from 2006 to 2022. A "treatment episode" was defined by refill continuity; a gap of more than 14 days in medication supply signaled the end of an episode.

The study integrated several high-value datasets:

  1. IQVIA PharMetrics Plus for Academics Closed: Longitudinal prescription and medical claims, primarily from commercially insured patients.
  2. CDC Social Vulnerability Index (SVI): A composite measure of community risk based on 15 variables (income, education, housing, transport, etc.).
  3. SAMHSA Provider Data: Locations of buprenorphine-waivered providers and licensed mental health/substance use treatment facilities.
  4. American Community Survey (ACS): Used for population-weighting and normalizing provider densities per 10,000 residents.

Patient ZIP codes (at the 3-digit level) were mapped to these external datasets. The team then employed stepwise multinomial logistic regression to estimate the odds of a patient falling into one of four duration categories: short-term (0–3 months), medium-term (3–6 months), extended medium-term (6–12 months), and long-term (>12 months).

Results

The study found that community-level factors are powerful predictors of treatment duration, with their influence often intensifying over time.

Forest plot of adjusted odds ratios for factors influencing buprenorphine treatment duration.

Key findings include:

  • Social Vulnerability: Individuals in the lowest-vulnerability areas had significantly higher odds of staying in treatment. For long-term retention (>12 months), the odds were 1.95 times higher (95% CI 1.89–2.02) compared to those in high-vulnerability areas.
  • Mental Health Synergy: Access to mental health services was a stronger predictor of long-term retention than the density of buprenorphine prescribers alone. High mental health service availability was associated with a 58% increase in the odds of long-term retention (OR 1.58).
  • Provider Density: High buprenorphine provider density led to a 10% increase in the odds of long-term retention (OR 1.10).
  • Telehealth: The data showed that individuals using telehealth services had significantly higher odds of long-term retention (OR 1.31), suggesting that removing geographic obstacles is a key policy lever.

The "Intensification" Effect

One of the most striking findings is that the influence of community factors increases as treatment duration gets longer. For example, living in a low-vulnerability area had a modest effect on medium-term retention but a massive effect on long-term retention. This suggests that structural barriers are cumulative; they might not stop someone from starting treatment, but they eventually "wear down" a patient's ability to stay on it.

Discussion and Limitations

Even after adjusting for community factors, disparities remained. Medicaid enrollees had lower odds of long-term retention (OR 0.88) compared to commercially insured patients, highlighting potential policy-driven barriers like prior authorization or lower reimbursement rates.

The authors acknowledge several limitations:

  • Claims data cannot capture the specific reasons for treatment discontinuation (e.g., side effects or personal preference).
  • The dataset lacked reliable data on race, ethnicity, and housing status.
  • The cohort was primarily commercially insured, so findings may not perfectly translate to the most marginalized populations.

Conclusion

Community-level factors like social vulnerability and local provider density are not just background noise; they are primary drivers of long-term OUD treatment retention. Addressing these structural access inequities and integrating mental health services could significantly improve outcomes for individuals with OUD. Future research should investigate the impact of long-acting injectable buprenorphine formulations, which could potentially bypass some of the daily access hurdles identified in this study.

Summary updated

Abstract

Social vulnerability, provider availability and mental health service access are significantly associated with buprenorphine treatment duration. Addressing these access inequities could improve retention for individuals with OUD.
BibTeX
@inproceedings{jaimesbuitron2025community,
  author = {Paula A Jaimes-Buitron and Kehe Zhang and Yanmin Gong and Yuanxiong Guo and Cici Bauer and Carolina Vivas-Valencia},
  title = {{Community-level factors influencing the duration of buprenorphine treatment in individuals with opioid use disorder: a cohort study using US longitudinal claims data}},
  booktitle = {BMJ},
  year = {2025},
  doi = {10.1136/bmjph-2025-003767},
}
Figure